Artigos de revistas sobre o tema "Finch, Pruyn and Company, Inc"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 15 melhores artigos de revistas para estudos sobre o assunto "Finch, Pruyn and Company, Inc".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Burmester, G. R., D. Aletaha, J. Pope, Y. Tanaka, P. Durez, A. Gomez-Centeno, A. Pechonkina et al. "THU0194 CHARACTERISATION OF DEPTH OF RESPONSE, INCLUDING 50% IMPROVEMENT IN ACR COMPONENTS AT WEEK 12 AND REMISSION AT WEEK 24, FOLLOWING TREATMENT WITH FILGOTINIB COMPARED WITH METHOTREXATE OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 316.1–317. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2236.
Texto completo da fonteCombe, B., A. Kivitz, Y. Tanaka, D. Van der Heijde, J. A. Simon-Campos, H. S. B. Baraf, U. Kumar et al. "THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 320–21. http://dx.doi.org/10.1136/annrheumdis-2020-eular.276.
Texto completo da fonteKivitz, A., Y. Tanaka, S. Lee, L. Ye, H. Hu, R. Besuyen e B. Combe. "FRI0128 FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, HEALTH-RELATED QUALITY OF LIFE, AND FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM THE FINCH 1 STUDY". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 645.2–646. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2882.
Texto completo da fonteTaylor, P. C., J. Liu, L. Zhuo, Y. Tian, T. Snyder, C. Kim, P. Kheradpour, K. Drake, S. Kim e R. E. Hawtin. "OP0100 MOLECULAR PROFILING OF PERIPHERAL IMMUNE CELL SUBSETS IN PATIENTS WITH RHEUMATOID ARTHRITIS". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 65.2–65. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3967.
Texto completo da fonteWalker, D., T. Takeuchi, B. Bartok, S. Rao, I. H. Lee, R. Besuyen, J. E. Gottenberg e M. C. Genovese. "FRI0139 FILGOTINIB PROVIDED RAPID AND SUSTAINED RELIEF OF PAIN AND FATIGUE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS: RESULTS FROM THE FINCH 2 STUDY". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 652–53. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2901.
Texto completo da fonteWinthrop, K., M. H. Buch, J. Curtis, G. R. Burmester, D. Aletaha, K. Amano, A. Pechonkina et al. "POS0092 HERPES ZOSTER IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de maio de 2021): 255.1–256. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1408.
Texto completo da fonteCombe, B., T. Matsubara, A. Pechonkina, Y. Tan, Z. Yin, J. Hong, R. Besuyen, A. Gomez-Centeno e M. H. Buch. "POS0657 GEOGRAPHIC VARIATION OF SAFETY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de maio de 2021): 569.2–570. http://dx.doi.org/10.1136/annrheumdis-2021-eular.643.
Texto completo da fonteGenovese, M. C., K. Winthrop, Y. Tanaka, T. Takeuchi, A. Kivitz, F. Matzkies, L. Ye et al. "THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 324–25. http://dx.doi.org/10.1136/annrheumdis-2020-eular.267.
Texto completo da fonteGottenberg, J. E., M. H. Buch, R. Caporali, G. C. Wright, T. Takeuchi, K. Kalunian, A. Pechonkina et al. "THU0204 A SUBGROUP ANALYSIS OF LOW DISEASE ACTIVITY AND REMISSION FROM PHASE 3 STUDY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARDS". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 326–27. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2237.
Texto completo da fonteBuch, M. H., T. Matsubara, B. Combe, A. Pechonkina, Y. Tan, Z. Yin, J. Hong, R. Besuyen e A. Gomez-Centeno. "POS0658 GEOGRAPHIC VARIATION OF EFFICACY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de maio de 2021): 570–71. http://dx.doi.org/10.1136/annrheumdis-2021-eular.648.
Texto completo da fonteGottenberg, J. E., G. R. Burmester, K. Van Beneden, C. Watson, I. Seghers, V. Rajendran, L. Dagna e M. H. Buch. "POS0513 SAFETY OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: ANALYSIS OF LYMPHOCYTES IN THE LONG-TERM EXTENSION FINCH 4 STUDY". Annals of the Rheumatic Diseases 81, Suppl 1 (23 de maio de 2022): 512–13. http://dx.doi.org/10.1136/annrheumdis-2022-eular.888.
Texto completo da fonteWinthrop, K., D. Aletaha, R. Caporali, Y. Tanaka, T. Takeuchi, P. Van Hoek, P. J. Stiers et al. "POS0844 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS WITH A MAXIMUM EXPOSURE OF 8.3 YEARS". Annals of the Rheumatic Diseases 82, Suppl 1 (30 de maio de 2023): 721–22. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1553.
Texto completo da fonteWalker, David, Kevin Winthrop, Mark C. Genovese, Bernard G. Combe, Yoshiya Tanaka, Alan Kivitiz, Franziska Matzkies et al. "O09 Pooled safety analyses from Phase 3 studies of filgotinib in patients with RA". Rheumatology 59, Supplement_2 (1 de abril de 2020). http://dx.doi.org/10.1093/rheumatology/keaa110.008.
Texto completo da fonteHerkness, Jenna, e Matthew Sims. "1839. Social Determinants of Health in Extended Spectrum Beta-Lactamase Carriage in the Urine – The Influence of Race, Ethnicity and Sex in the Outpatient Setting". Open Forum Infectious Diseases 10, Supplement_2 (27 de novembro de 2023). http://dx.doi.org/10.1093/ofid/ofad500.1668.
Texto completo da fonteGeurtsen, Jeroen, Joachim Doua, Luis Martinez-Martinez, Patricia Ibarra de Palacios, Jeff Powis, Matthew Sims, Peter Hermans et al. "2465. O-serotype Distribution of Escherichia coli Causing Invasive Disease in Tertiary Care Hospital Patients". Open Forum Infectious Diseases 10, Supplement_2 (27 de novembro de 2023). http://dx.doi.org/10.1093/ofid/ofad500.2083.
Texto completo da fonte